InspireMD (NSPR) AI Stock Analysis

• Market Cap: $100.96M
• Dividend Yield: N/A
• Average Volume (3M): 113.17K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.13
• Revenue Growth: 7.60%
• EPS Growth: -0.78%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -0.26
• Shares Outstanding: 41,720,660
• 10 Day Avg. Volume: 40,853
• 30 Day Avg. Volume: 113,167
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 14.13
• Enterprise Value/Gross Profit: 67.09
• Enterprise Value/Ebitda: -2.38
• 1Y Price Target: $3.83
• Price Target Upside: 60.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 50 Neutral
• Price Target: $2.50 ▲(5.04% Upside)

InspireMD's overall score reflects a mix of positive developments and ongoing challenges. The FDA approval and strong market reception for CGuard Prime are significant positives, but financial performance issues, including profitability and cash flow challenges, weigh heavily on the score. Technical indicators and valuation metrics also suggest caution.

Positive Factors

FDA Approval

The FDA approval allows InspireMD to enter the U.S. market, potentially increasing its market share and establishing a foothold in a lucrative market.

Strong Cash Position

A strengthened cash position enhances InspireMD's ability to fund its U.S. expansion and R&D, supporting long-term growth and market leadership.

Market Expansion

The U.S. launch of CGuard Prime expands InspireMD's market presence, leveraging its international experience to capture new opportunities and drive revenue growth.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, as indicated by negative margins, could hinder InspireMD's ability to sustain operations and invest in future growth.

Increased Operating Expenses

Rising operating expenses, driven by U.S. expansion, may pressure margins and require careful cost management to avoid eroding financial stability.

Cash Flow Issues

Negative cash flow indicates difficulties in generating sufficient cash from operations, potentially impacting InspireMD's ability to fund strategic initiatives.

InspireMD Business Overview & Revenue Model

Company Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

How the Company Makes Money

InspireMD generates revenue primarily through the sale of its CGuard™ embolic protection systems to hospitals and medical institutions. The company typically employs a direct sales model, complemented by partnerships with distributors to expand its market reach. Key revenue streams include product sales, with potential for recurring revenue through the sale of consumables related to its devices. Additionally, the company may benefit from strategic collaborations with other healthcare entities, which can include co-development agreements or distribution partnerships that enhance market access and drive sales growth.

InspireMD Financial Statement Overview

Summary

InspireMD shows revenue growth but faces significant profitability and cash flow challenges. The company maintains a strong equity position, yet ongoing operational losses and negative cash flows pose potential risks.

Income Statement

InspireMD has shown a consistent increase in revenue over the years, with a revenue growth rate of 12.95% from 2023 to 2024. However, the company struggles with profitability as indicated by its negative net profit margin of 22.22% in 2024 and a negative EBIT margin of 47.79%. The consistent negative EBITDA margin suggests ongoing operational challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 77.06% in 2024, indicating financial stability. However, the high debt-to-equity ratio of 0.05 suggests a manageable but present level of leverage. Return on equity is positive at 4.31% for 2024, indicating some profitability despite overall losses.

Cash Flow

InspireMD's cash flow statement reveals challenges in generating positive cash flows, with a significant negative free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating issues in translating income into cash. The free cash flow to net income ratio is also negative, further emphasizing liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.07M	7.01M	6.21M	5.17M	4.50M	2.48M
Gross Profit	1.49M	1.51M	1.81M	1.12M	754.00K	83.00K
EBITDA	-41.96M	-33.22M	-20.91M	-18.52M	-14.55M	-10.23M
Net Income	-41.38M	-32.01M	-19.92M	-18.49M	-14.92M	-10.54M
Balance Sheet
Total Assets	33.34M	46.81M	47.64M	24.65M	39.71M	17.78M
Cash, Cash Equivalents and Short-Term Investments	19.37M	34.64M	39.02M	17.80M	34.04M	12.64M
Total Debt	3.42M	2.34M	1.59M	1.61M	1.20M	999.00K
Total Liabilities	13.10M	10.72M	8.14M	7.26M	6.18M	5.61M
Stockholders Equity	20.24M	36.09M	39.50M	17.39M	33.53M	12.16M
Cash Flow
Free Cash Flow	-31.24M	-23.27M	-16.76M	-16.02M	-13.55M	-9.17M
Operating Cash Flow	-29.57M	-21.87M	-16.38M	-15.54M	-13.21M	-9.08M
Investing Cash Flow	9.34M	12.64M	-16.09M	8.44M	-22.46M	-187.00K
Financing Cash Flow	3.24M	18.45M	37.53M	-140.00K	35.03M	16.39M

InspireMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Negative. The current price of 2.38 is below the 20-day moving average (MA) of 2.43, below the 50-day MA of 2.44, and below the 200-day MA of 2.63, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.77 is Neutral, neither overbought nor oversold. The STOCH value of 31.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NSPR.

InspireMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	58 Neutral	$53.27M	48.68	-1.62%	―	3.30%	-112.70%
HYPR	57 Neutral	$106.08M	―	-77.26%	―	-9.59%	8.78%
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
NSPR	50 Neutral	$100.96M	―	-123.51%	―	7.60%	-0.78%
CTSO	46 Neutral	$59.83M	―	-68.84%	―	-7.81%	65.39%
ICCM	46 Neutral	$68.21M	―	-230.80%	―	-16.46%	4.14%
VANI	44 Neutral	$71.09M	―	-177.75%	―	―	4.91%

InspireMD Corporate Events

InspireMD Reports Q2 2025 Financial Results and Milestones

On August 5, 2025, InspireMD reported its financial results for the second quarter and the first half of 2025, highlighting significant milestones including FDA approval and the U.S. launch of its CGuard Prime carotid stent system. The company also secured $58 million through equity placement and warrant exercises, supporting its growth initiatives. Despite a slight increase in revenue, the company faced a net loss due to increased operating expenses related to sales force expansion and product launch preparations. InspireMD’s strategic moves are expected to position it as a leader in carotid artery disease treatment.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Raises $40.1M in Private Placement Offering

On July 30, 2025, InspireMD entered into a securities purchase agreement for a private placement offering, raising approximately $40.1 million through the sale of common stock and pre-funded warrants. The offering is expected to close by August 1, 2025, and includes a registration rights agreement to file a resale registration statement with the SEC. Additionally, InspireMD announced the full exercise of its Series I warrants, generating $17.9 million in gross proceeds, and the combined financings of $58 million will bolster the company’s balance sheet to commercialize its FDA-approved CGuard Prime carotid stent in the U.S. market. The company aims to use the proceeds for operations, including sales, marketing, and research and development, positioning itself as a leader in the carotid intervention market.

The most recent analyst rating on (NSPR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.